[Long-term immunologic response in HIV-infected patients with CD4 cell counts </= 50/mm3 when initiating protease inhibitor therapy]. 2001

V Le Moing, and Z Eid, and J L Ecobichon, and X Duval, and P Longuet, and C Elbim, and F Brun-Vezinet, and C Leport, and J L Vilde
Service des Maladies Infectieuses et Tropicales, Hôpital Bichat--Claude Bernard, Paris.

From March to July 1996, 61 patients with CD4<50/mm(3)began a therapy with protease inhibitors. Increase and maintenance of CD4>100/mm(3) was observed in 39/61 patients with a protective effect for occurrence of AIDS or death. This immunological response was correlated with the duration of the virological response. However, 38% of patients with long-term immunological response never had a undetectable viral load.

UI MeSH Term Description Entries
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D017320 HIV Protease Inhibitors Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly. HIV Protease Inhibitor,Inhibitor, HIV Protease,Inhibitors, HIV Protease,Protease Inhibitor, HIV,Protease Inhibitors, HIV
D018450 Disease Progression The worsening and general progression of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis. Clinical Course,Clinical Progression,Disease Exacerbation,Exacerbation, Disease,Progression, Clinical,Progression, Disease
D018791 CD4 Lymphocyte Count The number of CD4-POSITIVE T-LYMPHOCYTES per unit volume of BLOOD. Determination requires the use of a fluorescence-activated flow cytometer. Lymphocyte Count, CD4,T4 Lymphocyte Count,CD4 Cell Counts,CD4 Counts,CD4+ Cell Counts,CD4+ Counts,CD4 Cell Count,CD4 Count,CD4 Lymphocyte Counts,CD4+ Cell Count,CD4+ Count,Count, T4 Lymphocyte,Counts, T4 Lymphocyte,Lymphocyte Count, T4,Lymphocyte Counts, CD4,Lymphocyte Counts, T4,T4 Lymphocyte Counts
D019258 Saquinavir An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases, and also inhibits CYTOCHROME P-450 CYP3A. Invirase,Ro 31-8959,Saquinavir Mesylate,Saquinavir Monomethanesulfonate,Saquinivir,Monomethanesulfonate, Saquinavir,Ro 31 8959,Ro 318959
D019438 Ritonavir An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A. ABT 538,ABT-538,Norvir,ABT538

Related Publications

V Le Moing, and Z Eid, and J L Ecobichon, and X Duval, and P Longuet, and C Elbim, and F Brun-Vezinet, and C Leport, and J L Vilde
September 2005, The Journal of infectious diseases,
V Le Moing, and Z Eid, and J L Ecobichon, and X Duval, and P Longuet, and C Elbim, and F Brun-Vezinet, and C Leport, and J L Vilde
July 1998, AIDS (London, England),
V Le Moing, and Z Eid, and J L Ecobichon, and X Duval, and P Longuet, and C Elbim, and F Brun-Vezinet, and C Leport, and J L Vilde
April 2005, The Journal of allergy and clinical immunology,
V Le Moing, and Z Eid, and J L Ecobichon, and X Duval, and P Longuet, and C Elbim, and F Brun-Vezinet, and C Leport, and J L Vilde
November 2000, The American journal of gastroenterology,
V Le Moing, and Z Eid, and J L Ecobichon, and X Duval, and P Longuet, and C Elbim, and F Brun-Vezinet, and C Leport, and J L Vilde
January 2014, International journal of STD & AIDS,
V Le Moing, and Z Eid, and J L Ecobichon, and X Duval, and P Longuet, and C Elbim, and F Brun-Vezinet, and C Leport, and J L Vilde
May 2009, Current HIV research,
V Le Moing, and Z Eid, and J L Ecobichon, and X Duval, and P Longuet, and C Elbim, and F Brun-Vezinet, and C Leport, and J L Vilde
December 1996, Antiviral therapy,
V Le Moing, and Z Eid, and J L Ecobichon, and X Duval, and P Longuet, and C Elbim, and F Brun-Vezinet, and C Leport, and J L Vilde
February 2002, The Journal of infectious diseases,
V Le Moing, and Z Eid, and J L Ecobichon, and X Duval, and P Longuet, and C Elbim, and F Brun-Vezinet, and C Leport, and J L Vilde
August 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association,
V Le Moing, and Z Eid, and J L Ecobichon, and X Duval, and P Longuet, and C Elbim, and F Brun-Vezinet, and C Leport, and J L Vilde
December 2003, Lancet (London, England),
Copied contents to your clipboard!